Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce
Adi Mehta, Laura D Lomeli, Kevin M. Pantalone
Abstract
Early clinical trials suggested that patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists had a slightly increased risk of acute pancreatitis. Consequently, clinicians have avoided using GLP-1 receptor agonists in patients with a history of acute pancreatitis. However, recent large meta-analyses of clinical trial data do not support a class-wide risk. Denying these valuable therapeutic medications to patients with a history of pancreatitis seems unwarranted.
Topics & Concepts
MedicinePancreatitisGlucagon-like peptide-1ReceptorInternal medicineEndocrinologyDiabetes mellitusType 2 diabetesPancreatitis Pathology and TreatmentDiabetes Treatment and ManagementPancreatic and Hepatic Oncology Research